Long oppertunity HALO Halozyme Therapeutics Inc (Mid-Term)
Company showing a great increase in fundamental strength and many good highlights
Fundamental
- Expect to strongly grow 50-70% Cashflow per share.
- Expect to 20% grow in one year.
- Turnover is rapidly growing.
Fundamental
- Expect to strongly grow 50-70% Cashflow per share.
- Expect to 20% grow in one year.
- Turnover is rapidly growing.
免責事項
これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。